Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 607.5 SEK -0.57%
Market Cap: 36.4B SEK

Operating Margin
Camurus AB

39.4%
Current
25%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
39.4%
=
Operating Profit
927.2m
/
Revenue
2.4B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Camurus AB
STO:CAMX
36.3B SEK
39%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
27%
CH
Roche Holding AG
SIX:ROG
250.5B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP
24%
CH
Novartis AG
SIX:NOVN
202.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
206B USD
11%
US
Pfizer Inc
NYSE:PFE
146.7B USD
29%
No Stocks Found

Camurus AB
Glance View

Camurus AB is a Swedish pharmaceutical company that stands out in the industry with its innovative approach to treating chronic and rare diseases. Rooted in its proprietary FluidCrystal® injection depot technology, Camurus integrates this platform into the development of long-acting medications that aim to improve patient compliance and outcomes. This lipid-based system allows for the extended release of active substances, providing sustained therapeutic effects from just a single dose. Founded in 1991, the company has strategically focused its efforts on areas often underserved by traditional pharmaceutical giants, such as addiction, pain management, and endocrine disorders. By concentrating on these specific therapeutic areas, Camurus not only addresses significant health challenges but also carves out a niche with limited competition, potentially leading to substantial revenue streams. The company generates its income predominantly through product sales and strategic partnerships. One of its flagship products is Buvidal®, a long-acting medication for the treatment of opioid dependence, which has made significant inroads across Europe and Australia. The sustained revenue from Buvidal® highlights the company's adeptness at capitalizing on its technology to create tangible healthcare solutions. Additionally, Camurus engages in licensing agreements and collaborations with international pharmaceutical firms, expanding its market reach and leveraging its technology across a broader canvas. By investing heavily in research and development, Camurus ensures its pipeline continues to be robust, with new products consistently in various stages of clinical trials, thereby securing its financial performance and position in the pharmaceutical industry.

CAMX Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
39.4%
=
Operating Profit
927.2m
/
Revenue
2.4B
What is the Operating Margin of Camurus AB?

Based on Camurus AB's most recent financial statements, the company has Operating Margin of 39.4%.

Back to Top